NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
NanoStar Health aims to become a global leader in the emerging technology arena of nanomedical devices specifically designed for premature infants. The Company began operations in March 2009 and was incorporated in May 2009 to capitalize on the founder's expertise in nanotechnology, neonatal and pediatric medicine, and medical device commercialization.
An early stage therapeutic drug company, NanoVector Inc. is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University. The NanoVector nanoparticle is a plant virus. Central to our technology, this virus, which has evolved over millions of years, has several inherent characteristics essential for a successful nanoparticle delivery system and superior to any designed and engineered by humans.
NOD Pharmaceuticals uses patented platform technology, nanoparticle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.
OZ Biosciences creates, develops and produces innovative tools based on drug delivery systems for the worldwide scientific community and pharmaceutical industry. OZ Biosciences focuses on technologies for the delivery of bioactive materials into living organisms.
PDS Biotechnology Corporation is a biopharmaceutical company applying the company's platform Versamune nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.
PharmaNova Inc. is a privately held, specialty drug development company founded on the re-purposing and enhancement of known drugs using our proprietary nanoparticle technology platform and other complementary formulation and drug delivery technologies.
Pioneer Surgical Technology is a leading innovator in the design and manufacture of spinal and orthopaedic implants and instruments. The company's proprietary nanocrystalline hydroxyapatite technology - NanOss™ Bone Void Filler - is the first ever nanotechnology medical device to receive clearance by the US Food and Drug Administration (FDA). NanOss™ is an innovative structural biomaterial that is highly osteoconductive and remodels over time into human bone with applications in the sports medicine, trauma, spine and general orthopaedics markets.
PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to deliver easily and cost-effectively customized wound care on-demand for each patient's unique wound.
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.
A drug delivery company developing enhanced and improved therapeutic medicines in several fields. Solubest is using advanced polymer formulations to prepare nanotransporters for drugs having delivery or compliance insufficiencies.
Tempo is focused on significantly improving the efficacy and safety profile of existing and new drugs employing advances in nanotechnology. The Company utilizes its proprietary Nanocell™ technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle.
Vascular Magnetics, Inc. is magnetically targeting drug-loaded biodegradable nanoparticles to develop Vascular Magnetic Intervention (VMI), a novel therapy for peripheral artery disease (PAD). PAD is a common chronic condition characterized by obstruction (stenosis) of the arteries in the legs.
The company is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.